Challenges in Using MCDA for Reimbursement Decisions on New Medicines?-Reference-Cited by-同舟云学术

Challenges in Using MCDA for Reimbursement Decisions on New Medicines?

Published:2016-03 Issue:2 Volume:19 Page:123-124
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Walker Andrew

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference2 articles.

1. Timoney A. SMC modifiers used in appraising new medicines. 2012. Available from: http://www.scottishmedicines.org.uk/About_SMC/Policy_statements/SMC_Modifiers_used_in_Appraising_New_Medicines. [Accessed January 31, 2016].

2. Scottish Medicines Consortium. PACE (Patient & Clinician Engagement) overview document. Available from: http://www.scottishmedicines.org.uk/files/PACE/PACE_Overview_Document_FINAL.pdf. [Accessed January 31, 2016].

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel drug selection decision support model based on real-world medical data by the hybrid entropic weight TOPSIS method;Technology and Health Care;2023-03-15

2. Societal preferences for funding orphan drugs in China: An application of the discrete choice experiment method;Frontiers in Public Health;2022-12-12

3. HTA decision-making for drugs for rare diseases: comparison of processes across countries;Orphanet Journal of Rare Diseases;2022-07-08

4. Multiple criteria decision analysis for medicine reimbursement in the Lebanese context;International Journal of Technology Assessment in Health Care;2021

5. Framework for Drug Formulary Decision Using Multiple-Criteria Decision Analysis;Medical Decision Making;2020-04-26